From pharmacogenetics to pharmaco-omics: Milestones and future directions.
Details
![Ressource 1](https://serval.unil.ch/static/img/forbidden.png)
UNIL restricted access
State: Public
Version: author
License: CC BY 4.0
Serval ID
serval:BIB_4359AD13D7C0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
From pharmacogenetics to pharmaco-omics: Milestones and future directions.
Journal
HGG advances
ISSN
2666-2477 (Electronic)
ISSN-L
2666-2477
Publication state
Published
Issued date
14/04/2022
Peer-reviewed
Oui
Volume
3
Number
2
Pages
100100
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Abstract
The origins of pharmacogenetics date back to the 1950s, when it was established that inter-individual differences in drug response are partially determined by genetic factors. Since then, pharmacogenetics has grown into its own field, motivated by the translation of identified gene-drug interactions into therapeutic applications. Despite numerous challenges ahead, our understanding of the human pharmacogenetic landscape has greatly improved thanks to the integration of tools originating from disciplines as diverse as biochemistry, molecular biology, statistics, and computer sciences. In this review, we discuss past, present, and future developments of pharmacogenetics methodology, focusing on three milestones: how early research established the genetic basis of drug responses, how technological progress made it possible to assess the full extent of pharmacological variants, and how multi-dimensional omics datasets can improve the identification, functional validation, and mechanistic understanding of the interplay between genes and drugs. We outline novel strategies to repurpose and integrate molecular and clinical data originating from biobanks to gain insights analogous to those obtained from randomized controlled trials. Emphasizing the importance of increased diversity, we envision future directions for the field that should pave the way to the clinical implementation of pharmacogenetics.
Keywords
biobanks, bioinformatics, causal inference, electronic health records, genome-wide association studies, multi-omics, pharmacogenetics, pharmacogenome, pharmacogenomics
Pubmed
Web of science
Open Access
Yes
Create date
11/04/2022 8:39
Last modification date
29/07/2022 6:39